Pathfinder

pDNA vs. Synthetic / Enzymatic DNA: Which DNA Manufacturing Platform Is Better for Genetic Medicines?

Nice Insight

RNA

Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with Enzymatically Generated z- dbDNA

Lisa Caproni

Touchlight

Sustainability

Synthetic DNA Delivers a Sustainable Future for Genetic Medicines

Touchlight

Nonviral Delivery

Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA

Lisa Caproni

Touchlight

dbDNA

Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA

Jill Makin

Touchlight

Synthetic DNA

Transforming the Economics of AAV Manufacture While Optimizing Quality with dbDNA

Tom Merritt, Ph.D.

Touchlight

pDNA Manufacturing

Overcoming pDNA Supply Challenges for mRNA Manufacturing

Mack Kuo, Ph.D.

Synthetic DNA

Is Synthetic Plasmid DNA One of the Solutions for Meeting Growing Demand for Next-Gen Therapies?

David Alvaro, Ph.D.; Cynthia A. Challener, Ph.D.

Pharma's Almanac

Plasmid Manufacturing

Optimizing Plasmid Production to Meet Growing Demand

Danielle Alvarez; Cynthia A. Challener, Ph.D.

Pharma's Almanac

Plasmid DNA

Translating Three Decades of Experience in Plasmid DNA Into Customer Success

Thilo Kamphausen, Ph.D.; Kai Pohlmeyer, Ph.D.

Richter BioLogics

Plasmids

The Pivotal Role of Plasmid DNA

Robert Reames

Aldevron

Gene Therapy

Accelerating Innovation for Gene Therapy

Aldevron

AAV and LV Vectors

Supporting AAV and Lentiviral Vector Development and Commercialization

James Brown, Ph.D.

Aldevron